Heart in­flam­ma­tion emerges in a Sarep­ta Duchenne pa­tient, cloud­ing an oth­er­wise pos­i­tive read­out

Hav­ing al­ready se­cured sev­er­al ap­provals for Duchenne mus­cu­lar dy­s­tro­phy drugs, Sarep­ta aimed to cap­i­tal­ize on its lead in the field with a new da­ta read­out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER